CMS finalizes narrowed GLOBE model tying Medicare Part B drug payments to international prices
The mandatory international price benchmarking model will cover fewer drugs and produce far smaller savings than the original proposal, per STAT and policy trad
The Pharma Letter · +7 outlets
Trump signs executive order imposing 100% tariff on some pharmaceutical imports
The order targets branded and specialty drugs, with analysts warning of higher consumer costs for common medicines.
AOL.com · +13 outlets
Novo Nordisk to pay up to $2.6B to China's Hengrui for rights to a weekly GLP-1/GIP weight-loss pill
The licensing deal adds an oral incretin asset to Novo's pipeline as it defends its obesity franchise against Lilly.
Reuters · +14 outlets
Lilly's next-gen obesity drug retatrutide shows deeper weight loss in phase 3 data
Full phase 3 results position retatrutide, and a Zepbound-amylin combination, as Lilly's answer to intensifying obesity competition.
Fierce Biotech · +14 outlets
Regeneron says its drug halves muscle loss when combined with Novo's semaglutide in trial
Muscle preservation is emerging as a key differentiator as obesity drug developers target quality of weight loss, not just total pounds.
Reuters · +11 outlets
Zealand Pharma stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
Boehringer said it stands by the candidate despite the disappointing data from the partnered GLP-1/glucagon asset.
Fierce Biotech · +2 outlets
Lilly gives deeper look at Foundayo heart outcomes in diabetes and obesity phase 3
Cardiovascular benefit data are increasingly decisive for obesity drug reimbursement and label expansion.
Fierce Pharma · +2 outlets
Cullinan Therapeutics starts FDA NDA submission for zipalertinib combo in first-line EGFR exon 20 NSCLC
The filing follows phase 3 REZILIENT3 results, with an FDA decision date pending for the lung cancer regimen.
Quiver Quantitative · +9 outlets
Wave Life Sciences says FDA feedback supports registrational path for WVE-006 RNA editing in AATD
A one-year data check could enable faster approval for the first RNA-editing therapy in alpha-1 antitrypsin deficiency.
Yahoo Finance Australia · +9 outlets
European obesity meeting takeaways: Milan EASD data frame Lilly versus Novo showdown
The conference featured next-gen obesity candidates, muscle-sparing combinations and monthly dosing approaches from global and Korean developers.
BioPharma Dive · +4 outlets
Biopharma bets on GLP-1 drugs as anti-aging treatments beyond weight loss
Companies are studying whether incretins deliver broader cardiometabolic and longevity benefits as the obesity market matures.
헤럴드경제 · +11 outlets
Eli Lilly's Zepbound plus amylin drug drove significant weight loss in mid-stage trial
The combination approach is central to next-generation obesity strategies pairing incretins with amylin analogs.
STAT · +13 outlets
India's Supreme Court seeks uniform 16% retail markup cap on medicines
Judicial intervention on trade margins is raising questions about how drug pricing is regulated across Indian states.
Sahi · +14 outlets
Moderna stock falls as Citi downgrades, citing stretched valuation after 500% rally
The downgrade comes despite continued momentum in the company's cancer vaccine programs.
Investopedia · +1 outlets
FDA advisers narrowly vote to add six peptides to drug compounding list
The vote affects which compounded peptides remain available amid scrutiny of copycat GLP-1 products.
healthaffairs.org · +11 outlets
Karnataka flags 10 to 52 times markup on cancer drugs and consumables, seeks central intervention
State officials want federal action on hospital medicine pricing after finding large retail markups over procurement costs.
ETPharma.com · +2 outlets
Roche's experimental MS treatment cut relapse rates 58.5% versus standard care in trial
The data add to a crowded multiple sclerosis pipeline competing on relapse reduction.
stocktitan.net · +1 outlets
Roche's experimental MS treatment cut relapse rates 58.5% versus standard care in trial
The data add to a crowded multiple sclerosis pipeline competing on relapse reduction.
stocktitan.net · +1 outlets